Randomized Evaluation of Aggressive or Moderate Lipid Lowering Therapy with Pitavastatin in Coronary Artery Disease(REAL-CAD)
- Conditions
- Patients with stable coronary artery disease
- Registration Number
- JPRN-UMIN000002680
- Lead Sponsor
- Public Health Research Foundation
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 12600
Not provided
Exclusion Criteria(1) (Pre-Run-in period) 1. Patients planed revascularization 2. Malignant tumor in active phase 3. Patients who meet contraindication of LIVALO tablet below 1) Patients who have hypersensitivity to LIVALO tablet 2) Patients who have severe liver dysfunction or biliary atresia. 3)Patients who are being treated with cyclosporine 4) Pregnant women, women suspected of being pregnant, or lactating women 4. Patients who have heart failure NYHA III or greater 5. Patients undergoing dialysis 6. Patients with familial hypercholesterolemia 7. Patients registered in the other clinical trials 8. Patients with prohibited drugs 9. Patients who are ineligible in the opinion of the investigator Exclusion Criteria(2) (Post-Run-in period) 1. LDL-C is 120mg/dL or over after Run-in period 2. Patients with occurrence of acute coronary syndrome (AMI or Unstable angina) within 3 months 3. Patients who have been undergone PCI or CABG within 3 months 4. Compliance is less than 50% in Run-in period 5. Patients who met primary endpoint or adverse events in Run-in period and judged as ineligible in the opinion of the investigator 6. Patients who are ineligible in the opinion of the investigator
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method